Psilera, a leading biopharmaceutical company pioneering next-generation neuroplastogens and psychedelic therapies, announced the successful closing of an oversubscribed $8.8 million Series Seed extension funding round led by a syndicate of institutional and strategic investors.

Psilera is a leading biopharmaceutical company pioneering next-generation psychedelics and neuroplastogens. Their programs span a wholly owned pipeline of novel therapeutic neuroplastogens, including the lead compound PSIL-006. With a deep commitment to scientific excellence and to improving the patient experience, Psilera pioneers and engineers novel therapies through next-generation precision neuropharmacology.